Pamidronic acid

Generic Name: Pamidronic acid

Brand Names: Pamisol

Drug Type: Small Molecule

Chemical Formula: C_₃H_₁₁NO_₇P_₂

CAS Number: 40391-99-9

Unique Ingredient Identifier: OYY3447OMC

Background: Pamidronic acid is a second generation, nitrogen containing bisphosphonate similar to neridronic acid and alendronic acid. Pamidronic acid was first described in the literature in 1977. The second generation bisphosphonates are less common as third generation bisphosphonates, such as ibandronic acid, zoledronic acid, minodronic acid, and risedronic acid are becoming more popular.

Pamidronic acid was granted FDA approval on 31 October 1991.

Indication: Pamidronate is indicated to treat moderate to severe hypercalcemia of malignancy, moderate to severe Paget's disease of bone, osteolytic bone metastases of breast cancer, and osteolytic lesions of multiple myeloma.

Associated Conditions: Hypercalcemia of Malignancy, Osteolytic lesion, Paget’s Disease, Osteolytic Bone metastases

Clinical Trials

CHronic Nonbacterial Osteomyelitis International Registry

Recruiting

Conditions: Chronic Recurrent Multifocal Osteomyelitis
Chronic Nonbacterial Osteomyelitis

Interventions: Drug: NSAID
Drug: Methotrexate
Drug: Etanercept
Drug: Pamidronate
Drug: Sulfasalazine
Drug: Adalimumab
Drug: Zoledronic acid
Drug: Leflunomide
Drug: Certolizumab
Drug: Infliximab
Drug: Golimumab

First Posted Date: 2021-01-26

Last Posted Date: 2024-07-30

Lead Sponsor: Seattle Children's Hospital

Target Recruit Count: 2000

Registration Number: NCT04725422

Locations: 🇺🇸
Seattle Children's Hospital, Seattle, Washington, United States

Bisphosphonate Therapy in MONA Spectrum Disorder

Completed

Conditions: Bone Density
Fracture
Pain

First Posted Date: 2016-07-06

Last Posted Date: 2016-07-06

Lead Sponsor: Medical University Innsbruck

Target Recruit Count: 3

Registration Number: NCT02823925

4-weekly Versus 12-weekly Administration of Bone-targeted Agents in Patients With Bone Metastases

Phase 4

Completed

Conditions: Breast Cancer
Prostate Cancer
Metastasis

Interventions: Drug: Pamidronate
Drug: Denosumab
Drug: Zoledronate

First Posted Date: 2016-03-29

Last Posted Date: 2020-12-02

Lead Sponsor: Ottawa Hospital Research Institute

Target Recruit Count: 263

Registration Number: NCT02721433

Locations: 🇨🇦
The Ottawa Hospital Research Institute, Ottawa, Ontario, Canada

Efficacy of Bisphosphonates in Patients With Synovitis, Acne, Pustulosis, Hyperostosis, and Osteitis (SAPHO) Syndrome

Phase 1

Completed

Conditions: SAPHO Syndrome

Interventions: Drug: pamidronate disodium

First Posted Date: 2015-09-09

Last Posted Date: 2016-10-13

Lead Sponsor: Peking Union Medical College Hospital

Target Recruit Count: 30

Registration Number: NCT02544659

Combined Treatment With TNF Inhibitor and Pamidronate in AS Patients: Effect on the Radiographic Progression

Phase 4

Conditions: Ankylosing Spondylitis

Interventions: Other: Placebo (NaCl 0.9%)
Drug: Pamidronate

First Posted Date: 2014-12-10

Last Posted Date: 2014-12-10

Lead Sponsor: Bnai Zion Medical Center

Target Recruit Count: 30

Registration Number: NCT02313727

Locations: 🇮🇱
Bnai Zion Medical Center, Haifa, Israel

Evaluate Time Associated With the Preparation & Administration of Denosumab/Pamidronate in Patients With Solid Tumors and Metastatic Bone Disease

Phase 4

Withdrawn

Conditions: Metastatic Bone Disease
Solid Tumor

Interventions: Biological: denosumab
Drug: pamidronate

First Posted Date: 2014-04-02

Last Posted Date: 2015-02-18

Lead Sponsor: Amgen

Registration Number: NCT02101164

Prevention of Bone Loss After Pediatric Hematopoietic Cell Transplantation

Phase 2

Completed

Conditions: Osteopenia
Osteoporosis

Interventions: Drug: Pamidronate
Drug: Calcium and vitamin D

First Posted Date: 2014-02-28

Last Posted Date: 2024-02-20

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Target Recruit Count: 63

Registration Number: NCT02074631

Locations: 🇺🇸
University of Minnesota Amplatz Children's Hospital, Minneapolis, Minnesota, United States
🇺🇸
Seattle Children's Hospital, Seattle, Washington, United States